Brief: Alkermes Presents Detailed Positive Results From Vibrance-1 Phase 2 Study Of Alixorexton In Patients With Narcolepsy Type 1
08/09/2025 08:17
Sept 8 (Reuters) - Alkermes Plc ALKS.O: ALKERMES PRESENTS DETAILED POSITIVE RESULTS FROM VIBRANCE-1 PHASE 2 STUDY OF ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 1 AT WORLD SLEEP CONGRESS 2025 ALKERMES PLC - TO INITIATE GLOBAL PHASE 3 PROGRAM IN Q1 2026 ALKERMES PLC - ALIXOREXTON WELL TOLERATED AT ALL DOSES Source text: ID:nPn7Hj6Qva Further company coverage: ALKS.O ((Reuters.Briefs@thomsonreuters.com;))